Everolimus

Product NDC
70377-091
11-digit product format
703770091
Labeler code
70377
Product ID
70377-091_38b19b37-504e-24ed-7dbc-8b9f9e3fda0a
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Everolimus
Dosage form
TABLET, FOR SUSPENSION
Route
ORAL
Labeler
Biocon Pharma Inc.
Application
ANDA217216
Marketing category
ANDA
Marketing start
2026-01-14
Substance
EVEROLIMUS
Active strength
3 mg/1
Pharmacologic classes
Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 42.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A217216-001EVEROLIMUSEVEROLIMUS2MGTABLET, FOR SUSPENSION / ORALAB2026-01-09
A217216-002EVEROLIMUSEVEROLIMUS3MGTABLET, FOR SUSPENSION / ORALAB2026-01-09
A217216-003EVEROLIMUSEVEROLIMUS5MGTABLET, FOR SUSPENSION / ORALAB2026-01-09

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 3 matching rows.

Application-product, TE code table
Application-productTE code
A217216-001AB
A217216-002AB
A217216-003AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-08-18 06:07:402026-07A217216-001EVEROLIMUS2MGTABLET, FOR SUSPENSION / ORALAB2026-01-09caaa826d4ba7…
2026-08-18 06:07:402026-07A217216-002EVEROLIMUS3MGTABLET, FOR SUSPENSION / ORALAB2026-01-09caaa826d4ba7…
2026-08-18 06:07:402026-07A217216-003EVEROLIMUS5MGTABLET, FOR SUSPENSION / ORALAB2026-01-09caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A217216-001EVEROLIMUS2MGTABLET, FOR SUSPENSION / ORALAB2026-01-09011fe1cb6892…
2026-02-19 14:30 UTC2026-02A217216-002EVEROLIMUS3MGTABLET, FOR SUSPENSION / ORALAB2026-01-09011fe1cb6892…
2026-02-19 14:30 UTC2026-02A217216-003EVEROLIMUS5MGTABLET, FOR SUSPENSION / ORALAB2026-01-09011fe1cb6892…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217216-001EVEROLIMUS2MGTABLET, FOR SUSPENSION / ORALAB2026-01-09a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217216-002EVEROLIMUS3MGTABLET, FOR SUSPENSION / ORALAB2026-01-09a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217216-003EVEROLIMUS5MGTABLET, FOR SUSPENSION / ORALAB2026-01-09a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-08-18 06:07:402026-07A217216-001AB1caaa826d4ba7…
2026-08-18 06:07:402026-07A217216-002AB1caaa826d4ba7…
2026-08-18 06:07:402026-07A217216-003AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A217216-001AB1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A217216-002AB1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A217216-003AB1011fe1cb6892…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217216-001AB1a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217216-002AB1a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217216-003AB1a50c72e98297…

Additional Listing Data#

Finished product
Yes
Brand name base
Everolimus
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
EVEROLIMUS3 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
9HW64Q8G6GInternal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 3 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
1308428Internal RxNorm lookup
1308430Internal RxNorm lookup
1308432Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
5b809dfe-c076-07c5-207e-178c3f0d32d3Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
807eb842-6749-6eff-f9ce-2751c69fde93Product name420260122
151279ee-9f3c-b884-3327-05b3fa99d863Product name620251027

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
70377-091-11Everolimus28 in 1 BOTTLETABLET, FOR SUSPENSION285
70377-091-23Everolimus7 in 1 BLISTER PACKTABLET, FOR SUSPENSION75
70377-091-23Everolimus4 in 1 CARTONTABLET, FOR SUSPENSION45

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70377-091-23EA - Each70377-091eb216211-1e86-4979-a8c0-19eae9f09c9012026-02-05

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
EverolimusEVEROLIMUSBiocon Pharma Inc.5b809dfe-c076-07c5-207e-178c3f0d32d32026-06-30Warnings, Adverse reactionsExact identifier
application applno (ANDA): 217216
application number: ANDA217216
ndc (product): 70377-091

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
1308428everolimus 2 MG Tablet for Oral SuspensionPSN5b809dfe-c076-07c5-207e-178c3f0d32d35
1308430everolimus 3 MG Tablet for Oral SuspensionPSN5b809dfe-c076-07c5-207e-178c3f0d32d35
1308432everolimus 5 MG Tablet for Oral SuspensionPSN5b809dfe-c076-07c5-207e-178c3f0d32d35
1308428everolimus 2 MG Tablet for Oral SuspensionSCD5b809dfe-c076-07c5-207e-178c3f0d32d35
1308430everolimus 3 MG Tablet for Oral SuspensionSCD5b809dfe-c076-07c5-207e-178c3f0d32d35
1308432everolimus 5 MG Tablet for Oral SuspensionSCD5b809dfe-c076-07c5-207e-178c3f0d32d35

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startSampleExclude flagStatus
70377-091-117037700911128 TABLET, FOR SUSPENSION in 1 BOTTLE (70377-091-11) 2026-01-14NoNoCurrent
70377-091-23703770091234 BLISTER PACK in 1 CARTON (70377-091-23) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK4 blister pack2026-01-14NoNoCurrent